Journal of Leukocyte Biology eBioscience full spectrum cell analysis
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published online as doi:10.1189/jlb.0308165 on May 15, 2008

Published online before print May 15, 2008
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jlb.0308165v1
84/2/338    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Zheng, T. S.
Right arrow Articles by Burkly, L. C.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zheng, T. S.
Right arrow Articles by Burkly, L. C.
(Journal of Leukocyte Biology. 2008;84:338-347.)
© 2008 by Society for Leukocyte Biology

No end in site: TWEAK/Fn14 activation and autoimmunity associated- end-organ pathologies

Timothy S. Zheng1 and Linda C. Burkly

R&D-Immunology, Biogen Idec, Inc., Cambridge, Massachusetts, USA

1 Correspondence: R&D Immunology Biogen Idec, Inc., 14 Cambridge Center, Cambridge, MA 02142, USA. E-mail: timothy.zheng{at}biogenidec.com

Growing evidence suggests that the tumor necrosis factor superfamily (TNFSF) member TWEAK and its cognate receptor Fn14 play an important role in both physiological and pathological tissue remodeling. Herein, we review the various lines of experimental evidence that support the involvement of this ligand/receptor pair in triggering a wide range of cellular responses crucial to tissue remodeling, including angiogenic, proliferative, and inflammatory responses, and discuss the molecular mechanisms by which TWEAK/Fn14-induced tissue responses can lead to desired vs. undesired consequences in a context-dependent manner. We explore the key features of TWEAK-induced end-organ pathologies in various autoimmune disorders and the potential therapeutic benefits of TWEAK inhibition therein. We submit the viewpoint that TWEAK/Fn14-mediated pathogenic tissue remodeling represents an important, universal mechanism leading to various end-organ pathologies associated with autoimmune and inflammatory disorders. The highly specific and localized nature of its pathogenic contribution, therefore, makes the TWEAK/Fn14 pathway a unique and promising therapeutic target.

Key Words: inflammation • pathogenesis






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the Society for Leukocyte Biology.